Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer.
Ferry, David R
Margison, Jennifer M
Kerr, David J
Ranson, Malcolm R
AffiliationDepartment of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK.
MetadataShow full item record
AbstractSP1049C is a novel anticancer agent containing doxorubicin and two nonionic pluronic block copolymers. In preclinical studies, SP1049C demonstrated increased efficacy compared to doxorubicin. The objectives of this first phase I study were to determine the toxicity profile, dose-limiting toxicity, maximum tolerated dose and pharmacokinetic profile of SP1049C, and to document any antitumour activity. The starting dose was 5 mg m(-2) (doxorubicin content) as an intravenous infusion once every 3 weeks for up to six cycles. A total of 26 patients received 78 courses at seven dose levels. The dose-limiting toxicity was myelosuppression and DLT was reached at 90 mg m(-2). The maximum tolerated dose was 70 mg m(-2) and is recommended for future trials. The pharmacokinetic profile of SP1049C showed a slower clearance than has been reported for conventional doxorubicin. Evidence of antitumour activity was seen in some patients with advanced resistant solid tumours. Phase II trials with this agent are now warranted to further define its antitumour activity and safety profile.
CitationPhase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. 2004, 90 (11):2085-91 Br. J. Cancer
JournalBritish Journal of Cancer
- Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
- Authors: Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R, Rochlitz C
- Issue date: 2012 Dec
- Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.
- Authors: Unger C, Häring B, Medinger M, Drevs J, Steinbild S, Kratz F, Mross K
- Issue date: 2007 Aug 15
- A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
- Authors: Fokkema E, Verweij J, van Oosterom AT, Uges DR, Spinelli R, Valota O, de Vries EG, Groen HJ
- Issue date: 2000 Feb
- A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
- Authors: Valle JW, Armstrong A, Newman C, Alakhov V, Pietrzynski G, Brewer J, Campbell S, Corrie P, Rowinsky EK, Ranson M
- Issue date: 2011 Oct
- Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
- Authors: Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C
- Issue date: 1998